Neuropathic Pain - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Neuropathic Pain - Pipeline Review, H1 2016

Neuropathic Pain - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Neuropathic Pain - Pipeline Review, H1 2016
Published Jun 28, 2016
572 pages — Published Jun 28, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Neuropathic Pain - Pipeline Review, H1 2016, provides an overview of the Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain
- The report reviews pipeline therapeutics for Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neuropathic Pain therapeutics and enlists all their major and minor projects
- The report assesses Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neuropathic Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics&

  
Source:
Document ID
GMDHC7966IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents232
  List of Tables285
  List of Figures331
Introduction341
  Global Markets Direct Report Coverage341
Neuropathic Pain Overview351
Therapeutics Development362
  Pipeline Products for Neuropathic Pain Overview361
  Pipeline Products for Neuropathic Pain Comparative Analysis371
Neuropathic Pain Therapeutics under Development by Companies3812
Neuropathic Pain Therapeutics under Investigation by Universities/Institutes502
Neuropathic Pain Pipeline Products Glance524
  Late Stage Products521
  Clinical Stage Products531
  Early Stage Products541
  Unknown Stage Products551
Neuropathic Pain Products under Development by Companies5614
Neuropathic Pain Products under Investigation by Universities/Institutes702
Neuropathic Pain Companies Involved in Therapeutics Development72121
  2-BBB Medicines BV721
  AbbVie Inc.731
  Achelios Therapeutics, Inc.741
  Adynxx, Inc.751
  Aestus Therapeutics, Inc.761
  Affectis Pharmaceuticals AG771
  Amura Holdings Limited781
  AnaBios Corporation791
  Anavex Life Sciences Corp.801
  AngioChem Inc.811
  APT Therapeutics, Inc.821
  Arena Pharmaceuticals, Inc.831
  Asahi Kasei Pharma Corp.841
  Astellas Pharma Inc.851
  AstraZeneca Plc861
  BCI Pharma871
  BCN Peptides, S.A.881
  Benitec Biopharma Limited891
  BioDelivery Sciences International, Inc.901
  Biogen, Inc.911
  BioLineRx, Ltd.921
  Biomar Microbial Technologies931
  Bionomics Limited941
  Bristol-Myers Squibb Company951
  Can-Fite BioPharma Ltd.961
  Cara Therapeutics, Inc.971
  Catalyst Biosciences, Inc.981
  Cavion LLC991
  Centrexion Corporation1001
  Cerecor Inc.1011
  Chromocell Corporation1021
  Circuit Therapeutics, Inc.1031
  CLL Pharma1041
  Colby Pharmaceutical Company1051
  ContraVir Pharmaceuticals, Inc.1061
  Creabilis SA1071
  Crinetics Pharmaceuticals, Inc.1081
  Cytogel Pharma, LLC1091
  Daewoong Pharmaceutical Co., Ltd.1101
  Daiichi Sankyo Company, Limited1111
  DermaXon, LLC1121
  Develco Pharma Schweiz AG1131
  Dompe Farmaceutici S.p.A.1141
  Eisai Co., Ltd.1151
  Eli Lilly and Company1161
  Endece, LLC1171
  F. Hoffmann-La Roche Ltd.1181
  Genecode AS1191
  Glenmark Pharmaceuticals Ltd.1201
  Glialogix, Inc.1211
  Grunenthal GmbH1221
  GW Pharmaceuticals Plc1231
  Hydra Biosciences, Inc.1241
  Immune Pharmaceuticals Inc.1251
  Integral Molecular, Inc.1261
  IntelGenx Corp.1271
  Intellipharmaceutics International Inc.1281
  Jeil Pharmaceutical Co., Ltd.1291
  Jiangsu Nhwa Pharmaceutical Corporation Ltd.1301
  Johnson &Johnson1311
  Kareus Therapeutics, SA1321
  Kineta, Inc.1331
  Knopp Biosciences LLC1341
  Laboratorios Del Dr. Esteve S.A.1351
  LEO Pharma A/S1361
  Lexicon Pharmaceuticals, Inc.1371
  Lipopharma Therapeutics SL1381
  Lohocla Research Corporation1391
  Lpath, Inc.1401
  Mapi Pharma Ltd.1411
  Medestea Research &Production S.p.A.1421
  Medisyn Technologies, Inc.1431
  Medy-Tox Inc.1441
  Merck &Co., Inc.1451
  Nanomerics Ltd1461
  Nektar Therapeutics1471
  Neurim Pharmaceuticals Ltd1481
  Neurocentrx Pharma Ltd.1491
  Neurodyn Inc.1501
  NeurOp, Inc1511
  Newron Pharmaceuticals S.p.A.1521
  Nippon Chemiphar Co., Ltd.1531
  NoNO, Inc.1541
  Novaremed1551
  Novartis AG1561
  NsGene A/S1571
  Orion Oyj1581
  PeriphaGen, Inc.1591
  Pfizer Inc.1601
  Pharmaleads SA1611
  PharmEste1621
  Phosphagenics Limited1631
  Prismic Pharmaceuticals, Inc.1641
  RaQualia Pharma Inc.1651
  Re-Pharm Limited1661
  Recro Pharma, Inc.1671
  Relmada Therapeutics, Inc.1681
  Revance Therapeutics, Inc.1691
  Saniona AB1701
  Scilex Pharmaceuticals, Inc.1711
  Shionogi &Co., Ltd.1721
  Sigma-Tau S.p.A.1731
  SK Biopharmaceuticals Co., Ltd.1741
  Sphaera Pharma Pvt. Ltd.1751
  Spherium Biomed S.L.1761
  Sunovion Pharmaceuticals Inc.1771
  Syntrix Biosystems, Inc.1781
  Takeda Pharmaceutical Company Limited1791
  Teva Pharmaceutical Industries Ltd.1801
  Theranexus SAS1811
  Theravasc, Inc.1821
  Toray Industries, Inc.1831
  Torrent Pharmaceuticals Limited1841
  Trevena, Inc.1851
  Trigemina, Inc.1861
  Vichem Chemie Research Ltd.1871
  Virobay Inc.1881
  VistaGen Therapeutics , Inc.1891
  Yuhan Corporation1901
  Yungjin Pharm. Co., Ltd.1911
  Zynerba Pharmaceuticals, Inc.1921
Neuropathic Pain Therapeutics Assessment19336
  Assessment by Monotherapy Products1931
  Assessment by Combination Products1941
  Assessment by Target19513
  Assessment by Mechanism of Action20817
  Assessment by Route of Administration2252
  Assessment by Molecule Type2272
Drug Profiles229302
  (amitriptyline + ketamine hydrochloride) Drug Profile2294
  (clonidine hydrochloride + naltrexone hydrochloride) Drug Profile2331
  (diclofenac sodium + triclocarban) Drug Profile2341
  2-B3201 Drug Profile2352
  A-1262543 Drug Profile2371
  A-1264087 Drug Profile2381
  AFC-5128 Drug Profile2391
  AK-106 Drug Profile2401
  AM-3840 Drug Profile2411
  AN-363 Drug Profile2422
  AN-721 Drug Profile2441
  ANAVEX-1037 Drug Profile2451
  ANAVEX-1066 Drug Profile2461
  ANAVEX-1067 Drug Profile2471
  ANAVEX-1079 Drug Profile2481
  ANAVEX-1519 Drug Profile2491
  ANG-2002 Drug Profile2501
  AP-325 Drug Profile2511
  AP-61 Drug Profile2521
  APD-371 Drug Profile2531
  APT-102 Drug Profile2542
  AQU-010 Drug Profile2561
  AQU-118 Drug Profile2571
  AS-1069562 Drug Profile2581
  ATX-08001 Drug Profile2592
  AV-101 Drug Profile2613
  AXPN-03 Drug Profile2641
  AYX-3 Drug Profile2651
  BA-10 Drug Profile2661
  BBI-11008 Drug Profile2671
  BL-1110 Drug Profile2682
  bupivacaine hydrochloride Drug Profile2702
  C-746 Drug Profile2721
  capsaicin Drug Profile2731
  CC-8464 Drug Profile2742
  cebranopadol Drug Profile2763
  Cell Therapy for Central Nervous System Disorders Drug Profile2791
  cetuximab Drug Profile2806
  clonidine hydrochloride Drug Profile2863
  CLP-257 Drug Profile2891
  CMX-020 Drug Profile2901
  CNTX-6016 Drug Profile2911
  CNV-2197944 Drug Profile2922
  CPC-123 Drug Profile2941
  CR-4056 Drug Profile2951
  CR-701 Drug Profile2961
  CRB-0089 Drug Profile2971
  crotalphine Drug Profile2981
  CSTI-200 Drug Profile2991
  CT-340 Drug Profile3001
  Cyt-1010 Drug Profile3012
  daxibotulinumtoxin A Drug Profile3032
  DD-04107 Drug Profile3051
  DDD-028 Drug Profile3061
  DF-2593A Drug Profile3071
  dronabinol Drug Profile3081
  Drug for Cancer Neuropathic Pain Drug Profile3091
  Drug to Antagonize Interleukin-1 Receptor for Neuropathic Pain Drug Profile3101
  Drugs to Inhibit p38 MAP Kinase for Neuropathic Pain Drug Profile3111
  Drugs to Inhibit SRC-ND2 Interaction for Neuropathic Pain and Inflammatory Pain Drug Profile3121
  DSP-2230 Drug Profile3131
  duloxetine hydrochloride DR Drug Profile3142
  DWJ-208 Drug Profile3161
  DWP-05195 Drug Profile3171
  DX-0332 Drug Profile3181
  E-2072 Drug Profile3191
  EC-5026 Drug Profile3201
  ECL-1 Drug Profile3211
  EMA-401 Drug Profile3223
  etifoxine Drug Profile3251
  fadolmidine hydrochloride Drug Profile3261
  filgrastim Drug Profile3271
  Flexicaine Peel Drug Profile3281
  funapide Drug Profile3292
  FV-100 Drug Profile3314
  GERP-001 Drug Profile3351
  GLX-1112 Drug Profile3361
  GRC-17536 Drug Profile3372
  GRTTA-2210 Drug Profile3391
  HPI-201 Drug Profile3401
  HX-100 Drug Profile3412
  hydralazine hydrochloride Drug Profile3431
  IMB-1007 Drug Profile3441
  IPI-940 Drug Profile3451
  JNJ-40413269 Drug Profile3461
  JNJ-47965567 Drug Profile3471
  ketamine hydrochloride Drug Profile3482
  ketamine hydrochloride PR Drug Profile3501
  ketoprofen Drug Profile3511
  Kindolor Drug Profile3521
  KM-113 Drug Profile3531
  KM-314 Drug Profile3541
  L-779976 Drug Profile3551
  LASSBio-873 Drug Profile3561
  levorphanol tartrate ER Drug Profile3572
  lidocaine hydrochloride Drug Profile3591
  lidocaine hydrochloride patch Drug Profile3601
  LPA-181 Drug Profile3611
  Lpathomab Drug Profile3623
  LX-9211 Drug Profile3651
  MDA-7 Drug Profile3661
  MED-1101 Drug Profile3671

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Neuropathic Pain - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Neuropathic-Pain-Pipeline-Review-H1-2016-2088-16019>
  
APA:
Global Markets Direct - Market Research. (2016). Neuropathic Pain - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Neuropathic-Pain-Pipeline-Review-H1-2016-2088-16019>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.